A congressional commission on U.S.-China relations calls on Congress to authorize FDA to collect data from drug companies on where their drug components are made as part of an effort to reduce dependence on China for medicines.
CBS News says the federal patent office is taking steps to slow challenges to innovator biologic drug patents by biosimilar drug makers, while FDA is working to make the biosimilar approval process faster and less costly.
